Compare Heron Therapeutics Inc (HRTX) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Global X SuperDividend ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Global X SuperDividend ETF trades at $24.92. The key difference: Global X SuperDividend ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | SDIV | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.96 | $26.34 |
52-Week Low | $0.39 | $22.90 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
SDIV trades at $24.73, down 0.72% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The ETF offers a high dividend yield, recently paying $0.18 per share quarterly, attracting income-focused investors. Recent news highlights its role in diversified portfolios for retirees seeking steady cash flow, with a current yield around 9%.
Outlook remains positive for income investors due to high yield and diversification benefits, but risks include sensitivity to interest rates and economic cycles. Analyst sentiment is mixed, with some upgrades citing valuation support, while technical indicators suggest caution near-term. The fund's minimal tech exposure may appeal if market leadership broadens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
